{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-018704","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2026-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.522990+00:00","generated_at":"2026-05-16T08:40:33.298403+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction","bullets":["Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).","Median OS 16.0 months vs. 11.9 months (4.1-month improvement); both dual primary endpoints met.","NDA under FDA review with PDUFA date of July 11, 2026; MAA under EMA review.","Relacorilant well-tolerated without increased safety burden; no biomarker selection required.","Trial enrolled 381 patients across US, Europe, South Korea, Brazil, Argentina, Canada, Australia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-018704","json":"https://secwatch.observer/filing/0001193125-26-018704.json","markdown":"https://secwatch.observer/filing/0001193125-26-018704.md","text":"https://secwatch.observer/filing/0001193125-26-018704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526018704/0001193125-26-018704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526018704/d96058d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:40:33.298403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}